glp 1 y glp 2 This review summarizes how GLP-1 and dual GIP/GLP-1 receptor agonists act at the cellular level and their therapeutic applications in metabolic diseases like type diabetes and obesity, highlighting advances in incretin-based Main physiological actions of the

Semaglutide injection products have been on the FDA shortage list since 2022

These letters are in connection with the reducing group, thiol (-SH), in the glutathione molecule particularly in cysteine moiety

Key findings include: Dose-dependent improvements in neurological function scores at doses 2.5 ml/kg in rat models Reduced infarct volumes in middle cerebral artery occlusion (MCAO) models Enhanced functional recovery when combined with rehabilitation protocols Protection against excitotoxicity and oxidative stress in acute phase Studies using embolic stroke models showed that Cerebrolysin at 5 ml/kg significantly reduced lesion volume and improved sensorimotor outcomes when treatment began 4 hours post-stroke[8]

Cagrilintide combined with semaglutide (CagriSema) for treatment of type 2 diabetes In a recent small phase 2 trial (n=92), 3 groups of patients with type 2 diabetes were randomized to receive cagrilintide co-administered with semaglutide (the authors called this combination CagriSema), cagrilintide or semaglutide, both in doses escalated to 2.4 mg once weekly (table 1) [10]

(2009) Proc.Natl.Acad.Sci.U.S.A